Surrozen Inc (SRZN)

Surrozen's stock has experienced significant movement in the past six months, including a surge of over 106% and a recent 10% decline. Major shareholder Group Gp Lp Column III purchased shares totaling over $110,000 in January 2026, increasing their stake, and other insider buying activity was also reported. Surrozen reported its Q3 2025 earnings on November 7, 2025, posting an EPS of -$8.36, which significantly missed analysts' expectations. The company is expected to announce its next earnings report on March 30, 2026. An oversubscribed private placement of $175 million aimed at developing therapeutics for severe eye conditions was announced around August 2025. The stock has exhibited volatility over the past three months compared to the broader U.S. market.

Due to Surrozen, Inc.'s business model as a clinical-stage biotechnology company, there is no typical demand seasonality for its products and services. The company's revenue is primarily generated through partnerships, collaborations, research funding, milestone payments, and royalties from future product sales. Factors influencing its financial performance are more likely related to the progress and success of its research and development pipeline, clinical trial outcomes, regulatory approvals, and strategic alliances.

Surrozen, Inc. is a clinical-stage biotechnology company focused on discovering and developing drug candidates that modulate the Wnt pathway for tissue repair and regeneration, operating within the Health Technology sector, specifically in the Biotechnology and Drug Discovery industries. The company's primary focus has pivoted to its ophthalmology pipeline, leveraging its expertise in Wnt biology and antibody technologies to develop novel treatments for severe eye diseases. Its lead product candidates are antibody-based therapeutics targeting various disease areas, including SZN-8141, SZN-8143, SZN-113, and SZN-413 for ophthalmology, as well as SZN-043 and SZN-1326 for other disease areas. The company also has collaboration and license agreements, including one with Boehringer Ingelheim International GmbH and a research collaboration with TCGFB, Inc.

Surrozen, Inc.'s geographical markets primarily encompass North America and Europe, with global sales predominantly occurring in the U.S. The company is headquartered in South San Francisco, California, United States.

Surrozen, Inc. maintains a generally positive reputation within the financial and biotechnology communities, receiving a "Moderate Buy" consensus rating from analysts, with an average rating score of 2.67. MarketBeat's MarketRank™ scored Surrozen higher than 81% of companies evaluated in the medical sector, ranking it 139th out of 872 stocks. Its reputation is primarily influenced by its scientific advancements, progress in clinical trials, and financial stability. No specific events negatively impacting its brand reputation in the past year were identified beyond the general risks associated with clinical development and financial performance inherent in the biotechnology sector.

Approximately 66.57% of Surrozen, Inc.'s stock is held by institutional investors, while insiders hold 45.18%. Major institutional owners include StemPoint Capital LP, VR Adviser, LLC, Ra Capital Management, L.p., Vanguard Group Inc, 5AM Venture Management, LLC, Vivo Capital, LLC, Stonepine Capital Management, LLC, Samsara BioCapital, LLC, Nantahala Capital Management, LLC, Acuta Capital Partners, Llc, and The Column Group, LLC. The Column Group, LLC is a significant shareholder, holding 17% of outstanding shares as of November 2025.